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Abstract
Background: Diabetes mellitus (DM) is the leading cause of end-stage renal disease. Little is known about practice
patterns of anti-diabetic therapy in the presence of chronic kidney disease (CKD) and correlates with glycaemic
control. We therefore aimed to analyze current antidiabetic treatment and correlates of metabolic control in a large
contemporary prospective cohort of patients with diabetes and CKD.
Methods: The German Chronic Kidney Disease (GCKD) study enrolled 5217 patients aged 18–74 years with an
estimated glomerular filtration rate (eGFR) between 30–60 mL/min/1.73 m2 or proteinuria >0.5 g/d. The use of diet
prescription, oral anti-diabetic medication, and insulin was assessed at baseline. HbA1c, measured centrally, was the
main outcome measure.
Results: At baseline, DM was present in 1842 patients (35 %) and the median HbA1C was 7.0 % (25th–75th
percentile: 6.8–7.9 %), equalling 53 mmol/mol (51, 63); 24.2 % of patients received dietary treatment only, 25.5 % oral
antidiabetic drugs but not insulin, 8.4 % oral antidiabetic drugs with insulin, and 41.8 % insulin alone. Metformin was
used by 18.8 %. Factors associated with an HbA1C level >7.0 % (53 mmol/mol) were higher BMI (OR = 1.04 per increase
of 1 kg/m2, 95 % CI 1.02–1.06), hemoglobin (OR = 1.11 per increase of 1 g/dL, 95 % CI 1.04–1.18), treatment with insulin
alone (OR = 5.63, 95 % CI 4.26–7.45) or in combination with oral antidiabetic agents (OR = 4.23, 95 % CI 2.77–6.46) but
not monotherapy with metformin, DPP-4 inhibitors, or glinides.
Conclusions: Within the GCKD cohort of patients with CKD stage 3 or overt proteinuria, antidiabetic treatment
patterns were highly variable with a remarkably high proportion of more than 50 % receiving insulin-based therapies.
Metabolic control was overall satisfactory, but insulin use was associated with higher HbA1C levels.
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Background
Chronic kidney disease (CKD) is a major complication
of diabetes mellitus (DM) occurring in approximately
one third of diabetic patients. DM is the leading cause
for end-stage renal disease (ESRD) in most countries
worldwide [1]. CKD of all etiologies potentiates cardiovas-
cular disease (CVD) risk, depending on its severity [2].
The co-incidence of DM and CKD leads to a particularly
marked increase in CVD risk [3]. Given the increasing
prevalence of DM, the burden of diabetic kidney disease is
expected to further increase in the future [4].
Good glycaemic control is the mainstay for preventing
microvascular complications in patients with DM [5, 6].
Hemoglobin A1c (HbA1C), which reflects average gly-
caemic control over the past one to two months, has been
shown to better capture increased risk for adverse events
than plasma glucose [7]. Meta-analyses reported an in-
crease of CVD events by approximately 18 % per increase
of one percent of HbA1C [8]. HbA1C targets <7 % were
shown to slow the progression of kidney disease [5, 9]. In-
tensive compared to standard glycaemic control also re-
duced coronary events in type 2 DM in some [10], albeit
not all studies [11]. On the other hand the risk of severe
hypoglycemia is doubled during intensive treatment, espe-
cially when the eGFR is <60 mL/min/1.73 m2 [12].
There are multiple therapeutic options for glycaemic
control and they are likely to increase further with the
introduction of new oral antidiabetic drugs. However, no
clear recommendations exist for antidiabetic therapies in
patients with moderately severe CKD and individualized
treatment approaches and targets are so far recommended
[13]. Recommendations of regulatory agencies, such as
the FDA (Federal Drug Administration) for example for
the use of metformin were recently challenged.
Understanding treatment practice and the factors as-
sociated with good and poor metabolic control appears
important to assess the potential and limitations of dif-
ferent therapeutic regimes and to design future trials
comparing different treatment regimes prospectively.
Unfortunately, however, data about the use of different
glucose-lowering strategies and their combinations in
CKD patients are very sparse [14, 15]. We therefore de-
cided to analyze a large prospective database from German
kidney centers [16, 17], to understand how people with
type 2 DM and CKD are currently treated and which fac-
tors are associated with metabolic control and with the use
of the various classes of antidiabetic drugs.
Methods
Study population and design
The German Chronic Kidney Disease (GCKD) study is a
prospective observational cohort study of patients with
moderately severe CKD. It was approved by local ethics
committees and registered in the national registry of
clinical studies (DRKS 0003971). 5217 patients aged 18 to
74 years having either an estimated glomerular filtration
rate (eGFR) between 30–60 mL/min/1.73 m2 (according to
the 4-variable MDRD formula [18]) or proteinuria >0.5 g/
day (or equivalent measures) were enrolled across nine
German regional study centres after obtaining written in-
formed consent. All patients are under regular care by ne-
phrologists. Main criteria for exclusion from the GCKD
study were non-Caucasian ethnicity, the presence of active
malignancy, heart failure stage NYHA IV and any former
transplantations. A summary of the baseline data was
recently published [17]. Patients will be prospectively
followed for up to 10 years. Details of the study de-
sign, enrolment process and study procedures have
been reported [16].
During a structured interview at baseline each patient
was asked about concomitant diseases including previous
cardiovascular events; medications including antidiabetic
drugs and dietary therapy for diabetes were recorded. Drugs
were coded according to the Anatomical Therapeutic
Chemical (ATC) classification. The treating nephrologists
provided the patient’s medical history particularly of dia-
betes, kidney and CV diseases, and kidney biopsy reports.
Definition of diabetes mellitus
For study purposes, DM was defined according to ADA
criteria [19] when a HbA1C >6.5 % was present and/or
if a patient was treated with any antidiabetic drug or
antidiabetic diet.
Laboratory analysis
At baseline, blood, plasma, serum and spot-urine sam-
ples were collected from each patient according to
standard operation procedures, processed and shipped
frozen to the central laboratory [16]. HbA1C and
hemoglobin were determined from thawed whole blood.
HbA1C was measured using an International Federation
of Clinical Chemistry and Laboratory Medicine (IFCC)
proven immunoassay (Cobas Integra 400 Plus, ROCHE
Diagnostics, Switzerland). HbA1c results are reported in
both NGSP (%) and IFCC (mmol/mol) units. According
to recent recommendations, GFR was estimated using
the CKD-EPI formula [20].
Statistical methods
Baseline values of continuous variables are presented as
mean ± standard deviation or median with 25th, 75th per-
centiles. Values of categorical variables are presented as
numbers and percentages. Spearman rank correlation
coefficients were used to estimate correlation between
continuous variables. Kruskal-Wallis tests were used to
compare differences between independent groups of pa-
tients. In addition, Chi-Squared tests were used to evalu-
ate associations between categorical variables. Effects of
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treatment on HbA1C levels were estimated by using
stepwise logistic regression analysis with dependent vari-
able “HbA1C below/above median of 7 %”. This dichoto-
mization was chosen based on median calculation (see
below) and is in accordance with clinical relevance [21, 22]
and evidence reporting differences in outcomes in random-
ized controlled trials [10]. Using forward/backward step-
wise selection as well as the inclusion of all covariates,
models were adjusted for age, sex, body mass index (BMI),
duration of CKD, physical activity, eGFR, hemoglobin,
C-reactive protein, and antidiabetic medication (using
dietary treatment alone as the reference category). A
two-sided p value <0.05 was considered significant.
Statistical analyses were performed with SAS 9.2 (SAS
Institute, Inc., Cary, NC).
Results
Baseline characteristics
Diabetes was diagnosed in 1842 of the 5217 GCKD pa-
tients and differences between those with and without
diabetes have been published recently [17]. In brief, pa-
tients with DM were significantly older than patients
without DM (65 ± 8 vs. 58 ± 13 years, p < 0.001), and the
proportion of male patients was higher (67 vs. 56 %),
p < 0.001). Estimated GFR values were not significantly dif-
ferent (45 ± 16 mL/min/1.73 m2 in DM vs. 48 ± 17 mL/min/
1.73 m2 in Non-DM, p= 0.07). The same was true for the
urinary albumin/creatinine-ratio (UACR) (47 (9, 371) mg/g
in DM vs. 54 (9, 397) mg/g in Non-DM, p= 0.45). In 213
patients with DM (12 %), eGFR was >60 mL/min/1.73 m2.
Only 107 patients had type 1 diabetes (mean age 57.8 ±
11.3 years, 67 (63 %) male, median eGFR 45 mL/min/
1.73 m2 (36, 56), UACR 72 mg/g (8, 307). The self-reported
duration of DM was ≥5 years in 1046 patients (57 %), 1–5
years in 236 (13 %), and <1 year in 46 (2.5 %). In 514 pa-
tients the duration of DM was not known (28 %) and thus
this factor was excluded from further statistical analysis. As
main cause of CKD, the treating nephrologists listed diabetic
nephropathy in 40 %, vascular nephropathy in 17 %,
glomerulonephritis in 8 %, interstitial nephritis in 3 %, sys-
temic disease in 3 %, and miscellaneous in 29 %. The rate
of self-reported diabetic retinopathy was 20 % (n = 376).
The median HbA1C value of the study cohort was
7.0 % (6.8, 7.9), 53 mmol/mol (51, 63). Clinical data of
patients with DM stratified according to their baseline
HbA1C (equal or below vs above median) are shown in
Table 1. Most characteristics were similar between both
groups, except that patients with an HbA1C ≤7.0 % were
on average one year older, had slightly lower systolic
blood pressure and BMI, lower UACR and CRP.
Antidiabetic treatment
Roughly one quarter of the patients with DM were
treated with an antidiabetic diet regimen only (24.2 %),
or received oral antidiabetic drugs, but no insulin
(25.5 %). The majority was treated with insulin only
(41.8 %) and a small group was on insulin and oral anti-
diabetic agents (8.4 %) (Table 2). Differences across
groups of different therapeutic strategies including clas-
ses of oral antidiabetic drugs, alone or in combination,
are presented in Table 2. Patients who were treated with
insulin alone were significantly younger but exhibited
more advanced kidney disease with a lower eGFR and
higher UACR. Moreover, they had the highest rate of
pre-existing CVD; 88 out of the 699 patients in this
group had type 1 diabetes. The opposite was true for pa-
tients being treated with oral antidiabetic drugs but not
insulin. These patients had the highest eGFR, the lowest
UACR, and the lowest rate of CVD. Their HbA1C was
significantly lower (6.7 % (6.3, 7.3), 50 mmol/mol (45,
56)) as compared to the groups being treated with insu-
lin, either alone (7.5 % (6.8, 8.4), 58 mmol/mol (51, 68)),
or in the combination with oral antidiabetic drugs (7.5 %
(6.8, 8.4), 58 mmol/mol (51, 68), p < 0.0001 resp.). Almost
one fifth of patients (18.8 %) received metformin alone or
in any combination. In this group, eGFR was significantly
higher as compared to patients not using metformin (53
(43, 62) vs. 42 (34, 52) mL/min/1.73 m2, p < 0.0001). The
lowest UACR (29 mg/g (6, 202)) was observed in those
treated with DPP-4 inhibitors, alone or in combination.
Only a small minority of 2.4 % (n = 45) were treated by
GLP-1-agonists, either alone or in different combinations
and were thus excluded from further statistical analysis.
The eleven most commonly used antidiabetic regimes,
based on individual drugs and the corresponding clinical
data are presented in Table 3. The metformin alone
group showed the lowest HbA1C of 6.6 % (6.3, 7.1),
49 mmol/mol (45, 54) and the highest eGFR (56 ±
18 mL/min/1.73 m2) in combination with the lowest
UACR (22 mg/gCrea (5, 247)). The highest levels of
HbA1C were found in the small number of patients
treated with insulin and sulfonylureas (7.8 % (7.0, 8.6),
62 mmol/mol (53, 70)) followed by patients who were
treated with insulin and DPP-4 inhibitors having an
HbA1C of 7.6 % (6.6, 8.7), 60 mmol/mol (47, 72). These
two groups had the lowest average eGFR levels (42 ± 12
and 41 ± 12 mL/min/1.73 m2, respectively).
Glycaemic control and hemoglobin
The distribution of the HbA1C values is shown in Fig. 1.
A great number of patients cluster around the median of
7.0 % (53 mmol/mol). Fourtyfive percent of the patients
had HbA1C values within a range of 6.5–7.5 % (48–
58 mmol/mol), 20 % below 6.5 %, and 35 % ≥7.5 %. There
was a slight positive correlation of hemoglobin with
HbA1C (r = 0.082, p = 0.001, Additional file 1: Figure S1)
and eGFR (r = 0.247, p < 0.0001, Additional file 2: Figure
S2). No significant association of HbA1C with eGFR was
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Table 1 Baseline data of 1842 patients with diabetes mellitus and CKD stratified by median HbA1C levels (7.0 %, 53 mmol/mol)
HbA1C≤ 7.0 % (53 mmol/mol) n = 897 HbA1C > 7.0 % (53 mmol/mol) n = 945
Epidemiological data
Age (years) 65 ± 8 64 ± 8
Male, number (%) 591 (65.9) 637 (67.4)
Systolic blood pressure (mm Hg) 141 ± 22 143 ± 21
Diastolic blood pressure (mm Hg) 76 ± 12 76 ± 12
BMI (kg/m2) 32 ± 6 33 ± 6
Current smokers, number (%) 127 (14.2) 142 (15.0)
Duration of CKD
≥ 5 years 369 (41.2) 413 (43.7)
3 – < 5 years 133 (14.8) 162 (17.1)
1 – < 3 years 207 (23.1) 198 (21.0)
< 1 year 154 (17.2) 130 (13.8)
Physical activity
Less than once a week 173 (19.3) 201 (21.3)
1–2 times a week 202 (22.6) 221 (23.4)
3–5 times a week 256 (28.6) 236 (25.0)
More than 5 times a week 251 (28.0) 278 (29.5)
CV disease, number (%) a 403 (44.9) 463 (49.0)
Laboratory data
Creatinine (mg/dL) 1.47 (1.23, 1.80) 1.50 (1.27, 1.83)
eGFR (mL/min/1.73 m2) 44 (35, 55) 44 (35, 54)
eGFR 0–29 126 (14.1) 125 (13.6)
eGFR 30–44 322 (36.1) 346 (37.6)
eGFR 45–59 296 (33.2) 301 (32.7)
eGFR≥ 60 148 (16.6) 149 (16.2)
Urinary albumin/creatinine-ratio (mg/gCrea) 34 (7, 330) 59 (10, 412)
< 30 420 (48.4) 356 (38.7)
30–300 216 (24.9) 298 (32.4)
> 300 231 (26.6) 266 (28.9)
Hemoglobin (g/dL) a 13.4 (12.1, 14.5) 13.6 (12.5, 14.5)
HbA1C (%) 6.6 (6.3, 6.8) 7.9 (7.4, 8.6)
HbA1C (mmol/mol) 49 (45, 51) 63 (57, 70)
Serum albumin (g/L) 38.6 (35.9, 40.6) 38.1 (35.6, 40.5)
CRP (mg/L) 2.50 (1.24, 5.78) 3.13 (1.47, 6.73)
Calcium (mmol/L) 2.27 (2.18, 2.35) 2.28 (2.19, 2.36)
Phosphate (mmol/L) 1.11 (0.97, 1.25) 1.09 (0.96, 1.23)
Ca/Ph-Produkt (mmol2/L2) 2.03 (1.79, 2.33) 2.06 (1.79, 2.33)
Total cholesterol (mg/dL) b 194.9 (167.4, 228.8) 192.2 (161.2, 223.7)
HDL (mg/dL) b 45.1 (37.4, 55.7) 43.2 (35.8, 53.4)
LDL (mg/dL) b 103.1 (82.9, 131.8) 99.4 (75.3, 124.3)
TG (mg/dl) c 180.9 (125.5, 259.8) 197.1 (134.8, 279.4)
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found. Median HbA1c among the 107 patients with type 1
DM was 7.9 % (7.1, 8.8), 63 mmol/mol (54, 73), which was
significantly higher compared with patients having type
2 DM (n = 1678, HbA1C 7.0 % (6.5, 7.8), 53 mmol/mol
(48, 62), p < 0.0001).
Factors associated with HbA1C
Factors associated with an HbA1C level above the me-
dian of 7.0 % (53 mmol/mol) were determined. For this
analysis, clinical parameters (see method section) and
different treatment strategies (oral and/or insulin treat-
ment, dietary treatment as reference, see Table 2) were
included. Factors significantly associated with an HbA1C
level >7.0 % were higher body mass index (OR 1.038, p
< 0.0001) and higher hemoglobin (OR 1.112, p = 0.001,
Table 4). The use of oral antidiabetic drugs alone was
not significantly associated with the probability of a me-
dian HbA1C >7.0 % (Table 4). Excluding the use of sul-
fonylureas did not increase the probability of an HbA1C
>7.0 % in those receiving oral anti-diabetic drugs only
(OR 0.898, 95 % CI 0.625–1.291, p = 0.56). The use of in-
sulin, either alone (OR 5.634, p < 0.0001) or in the com-
bination with oral antidiabetic drugs (OR 4.233, p <
0.0001), was significantly associated with median HbA1C
levels >7.0 %. The entire model is presented in Add-
itional file 3: Table S1.
We further analyzed the association of different treat-
ment groups as outlined in Table 3 with HbA1C: The
use of insulin, either alone or in combination with sulfo-
nylureas, metformin, or DPP-4 inhibitors was signifi-
cantly associated with median HbA1C levels >7.0 % (OR
between 3.373 and 7.726, p < 0.0001, Additional file 4:
Table S2). In contrast, the monotherapy with oral antidi-
abetic drugs such as metformin (OR 0.895, p = 0.0002),
DPP-4 inhibitors (OR 0.864, p = 0.0117), or glinides (OR
0.898, p = 0.0069), and the combination of metformin
with DPP-4 inhibitors (OR 0.970, p = 0.0417) was signifi-
cantly associated with a decreased probability of median
HbA1C levels >7.0 %. Instead, treatment with sulfonyl-
ureas, either alone (OR 1.636, p = 0.31) or in the
combination with metformin (OR 3.497, p = 0.07) or in-
sulin (OR 7.726, p = 0.0002) was associated with an in-
creased probability of median HbA1C levels >7.0 %
(Additional file 4: Table S2). The entire model is given in
Additional file 5: Table S3.
Discussion
This study describes antidiabetic treatment reality in a
large cohort of CKD patients with DM. All patients were
under routine care of nephrologists and some of them
were additionally seen by diabetologists, so that the data
have to be interpreted as refecting specialist care.
A major finding of the analysis is that given the me-
dian HbA1C of 7.0 % (53 mmol/mol) [21, 22], the over-
all quality of DM control appears to be satisfactory in
most of the patients despite the combination of CKD
and DM. The treatment quality is comparable or even
better than in large cohort studies of people with type 2
diabetes in Germany that have found mean HbA1C
values of 7.0 and 7.2 % [23, 24]. German guidelines rec-
ommend an HbA1C between 6.5 and 7.5 % (48–
58 mmol/mol) for all patients with DM irrespective of
concomitant kidney disease [22] and 45 % of our cohort
met this criterium. The current U.S. National Kidney
Foundation’s Kidney Disease Outcome Initiative (K/
DOQI) guidelines recommend a target HbA1C “of
~7.0 % to prevent or delay progression of the microvascu-
lar complications of DM, including diabetic kidney dis-
ease” [21]. Thus, many of our patients were treated
according to these guidelines. Other studies also confirm
that good metabolic control can be achieved in patients
with DM and CKD. In a Canadian population based
study with 23,296 participants with DM and an eGFR of
lower than 60 mL/min/1.73 m2, but not on dialysis, a
median HbA1C level of 6.9 % was found [25]. This study
also reported an increase in the risk of mortality at
HbA1C levels of >8.0 and <6.5 % [25]. In this regard, it
is noteworthy that 20 % of our cohort had an HbA1C
below 6.5 % (48 mmol/mol), which might even suggest
overtreatment or poor health status with an increased
Table 1 Baseline data of 1842 patients with diabetes mellitus and CKD stratified by median HbA1C levels (7.0 %, 53 mmol/mol)
(Continued)
Antidiabetic treatment strategies
Dietary treatment alone 292 (35.1) 113 (13.5)
Oral anti-diabetic drugs alone, any 277 (33.3) 149 (17.8)
Oral anti-diabetic drugs plus insulin 49 (5.9) 92 (10.9)
Insulin alone 214 (25.7) 485 (57.8)
Values are reported as mean values ± standard deviation, medians (25th, 75th percentile), or numbers (percentages), as appropiate. a The composite of
cardiovascular disease includes all patients with one or more of the following: cardiac valve replacement, aortic aneurysm, coronary artery disease, cerebrovascular
disease, peripheral artery disease
a For conversion into SI units (mmol/L): multiply with 0.62
b For conversion into SI units (mmol/L): multiply with 0.02586
c For conversion into SI units (mmol/L): multiply with 0.0114
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Insulin alone P-value a Classes of oral antidiabetic drugs, alone or in combination
Metformin Sulfonyl-ureas Glinides DPP-4-inhibitors
Number 405 426 141 699 346 265 119 191
Percent 24.2 25.5 8.4 41.8 18.8 14.4 6.5 10.4
Age, years 65 ± 8 65 ± 7 65 ± 7 64 ± 9 0.0377 64 ± 8 67 ± 6 66 ± 6 65 ± 7
Male, n (%) 270 (66.7) 282 (66.2) 89 (63.1) 478 (68.4) 0.64 213 (61.6) 175 (66.0) 92 (77.3) 129 (67.5)
BMI, kg/m2 31 ± 6 32 ± 6 35 ± 6 32 ± 6 <0.0001 33 ± 6 33 ± 6 32 ± 6 34 ± 6
Hemoglobin, g/dL c 13.6 (12.5, 14.8) 13.5 (12.2, 14.5) 13.6 (12.6, 14.5) 13.3 (12.2, 14.4) 0.0833 13.6 (12.3, 14.7) 13.4 (12.5, 14.5) 13.5 (12.5, 14.6) 13.6 (12.5, 14.6)
HbA1c, % 6.7 (6.5, 7.1) 6.7 (6.3, 7.3) 7.5 (6.8, 8.4) 7.5 (6.8, 8.4) <0.0001 6.9 (6.4, 7.6) 7.1 (6.5, 7.9) 6.8 (6.5, 7.6) 6.9 (6.4, 7.7)
HbA1c, mmol/mol 50 (48, 54) 50 (45, 56) 58 (51, 68) 58 (51, 68) 52 (46, 60) 54 (48, 63) 51 (48, 60) 52 (46, 61)
eGFR, mL/min/1.73 m2 44 (35, 55) 48 (38, 58) 46 (37, 56) 41 (33, 51) <0.0001 53 (43, 62) 45 (36, 55) 42 (33, 50) 47 (36,56)
UACR, mg/gCrea 34 (8, 253) 31 (8, 322) 52 (9, 333) 71 (11, 512) 0.0011 38 (7, 369) 50 (9, 329) 45 (9, 371) 29 (6, 202)
CV disease, n(%)b 176 (43.5) 169 (39.7) 72 (51.1) 382 (54.7) <0.0001 141 (40.7) 120 (45.3) 46 (38.7) 88 (46.1)
Duration of CKD
≥ 5 years 183 (45.3) 152 (35.7) 56 (39.7) 324 (46.4) 0.0021 121 (34.9) 99 (37.4) 50 (42.0) 68 (35.6)
3 – < 5 years 65 (16.1) 63 (14.8) 23 (16.3) 115 (16.5) 50 (14.5) 35 (13.2) 20 (16.8) 28 (14.7)
1 – < 3 years 80 (19.8) 108 (25.3) 25 (17.7) 152 (21.8) 81 (23.4) 69 (26.0) 30 (25.2) 47 (24.6)
< 1 year 63 (15.6) 84 (19.7) 22 (15.6) 84 (12) 66 (19.1) 50 (18.9) 17 (14.3) 41 (21.4)
Values are reported as numbers and percentages (based on all diabetic patients), mean values ± standard deviation, or medians (25th, 75th percentile), as appropiate
Missings (n = 171) resulted mostly from combinations that were used less frequently
a according to Kruskal-Walis test, analysis of variance, or Chi-Square test, as appropriate
b The composite of cardiovascular disease includes all patients with one or more of the following: cardiac valve replacement, aortic aneurysm, coronary artery disease, cerebrovascular disease, peripheral artery disease












Table 3 Patient characteristics according to treatment with the 11 most commonly used antidiabetic treatment strategies in 1842 patients with diabetes mellitus and CKD
Insulin Dietary
treatment
Metformin Sulfonyl-ureas Metformin +
Insulin










N 699 405 123 123 76 59 46 38 38 37 27
Percent 41.8 24.2 7.4 7.4 4.6 3.5 2.8 2.3 2.3 2.2 1.6
Age, years 64 ± 9 65 ± 8 64 ± 9 67 ± 6 64 ± 7 66 ± 6 65 ± 7 66 ± 5 66 ± 6 64 ± 8 65 ± 7
Male gender, n (%) 478 (68.4) 270 (66.7) 70 (56.9) 80 (65.0) 46 (60.5) 45 (76.3) 36 (78.3) 29 (76.3) 27 (71.1) 22 (59.5) 16 (59.3)
BMI, kg/m2 32 ± 6 31 ± 6 33 ± 6 32 ± 5 35 ± 5 31 ± 5 34 ± 5 33 ± 6 34 ± 8 32 ± 5 36 ± 6
Hemoglobin, g/dL b 13.2 (12.2, 14.4) 13.6 (12.5, 14.8) 13.7 (12.2, 5.0) 13.4 (12.3, 14.5) 13.7 (12.4, 14.4) 13.5 (12.4, 14.5) 13.1 (12.1, 14.3) 13.1 (12.1, 14.4) 13.7 (12.7, 14.7) 14.1 (12.5, 15.1) 13.5 (12.8, 14.1)
HbA1c, % c 7.5 (6.8, 8.4) 6.7 (6.5, 7.1) 6.6 (6.3, 7.1) 6.8 (6.3, 7.5) 7.3 (6.8, 8.1) 6.7 (6.3, 7.0) 6.7 (6.3, 7.1) 7.3 (6.6, 7.9) 7.8 (7.0, 8.6) 6.7 (6.4, 7.2) 7.6 (6.6, 8.7)
eGFR, mL/min/
1.73 m2
43 ± 15 46 ± 17 56 ± 18 45 ± 12 55 ± 17 42 ± 10 45 ± 13 52 ± 16 42 ± 12 53 ± 17 41 ± 12
UACR, mg/gCrea 71 (11, 512) 34 (8, 253) 22 (7, 322) 45 (8, 319) 59 (7, 353) 51 (8, 245) 22 (5, 247) 56 (14, 408) 81 (12, 357) 29 (6, 441) 29 (14, 102)
Duration of CKD, n (%)
≥ 5 years 324 (46.4) 183 (45.3) 38 (30.9) 47 (38.2) 32 (42.1) 27 (45.8) 16 (34.8) 10 (26.3) 14 (36.8) 14 (37.8) 10 (37)
3 – < 5 years 115 (16.5) 65 (16.1) 19 (15.5) 17 (13.8) 13 (17.1) 10 (17) 9 (19.6) 6 (15.8) 4 (10.5) 2 (5.4) 6 (22.2)
1 – < 3 years 152 (21.8) 80 (19.8) 29 (23.6) 33 (26.8) 11 (14.5) 15 (25.4) 9 (19.6) 11 (29) 10 (26.3) 11 (29.7) 4 (14.8)
< 1 year 84 (12) 63 (15.6) 27 (22) 25 (20.3) 11 (14.5) 6 (10.2) 11 (23.9) 7 (18.4) 5 (13.2) 8 (21.6) 6 (22.2)
CV disease, number
(%) a
382 (54.7) 176 (43.5) 38 (30.9) 58 (47.2) 38 (50) 17 (28.8) 17 (37) 23 (60.5) 16 (42.1) 16 (43.2) 18 (66.7)
Values are reported as numbers and percentages (based on all diabetic patients), mean values ± standard deviation, or medians (25th, 75th percentile), as appropriate
Missings (n = 171) resulted mostly from combinations that were used less frequently
a The composite of cardiovascular disease includes all patients with one or more of the following: cardiac valve replacement, aortic aneurysm, coronary artery disease, cerebrovascular disease, peripheral artery disease
b For conversion of hemoglobin into SI units (mmol/L): multiply with 0.62












risk of hypoglycemia [26]. On the other hand 24.7 % of
patients with DM and CKD in the GCKD study had an
HbA1C >8.0 % (64 mmol/mol), indicating relevant het-
erogeneity and opportunities for improvement.
Interestingly the median dichotomization of our total
cohort with a median HbA1C of 6.6 % (49 mmol/mol)
in the lower group and a median of 7.9 % (63 mmol/
mol) in the higher group corresponds to an intensive
versus standard treatment approach when compared
with the mean HbA1C values of the intensive (6.7 %,
50 mmol/mol) and standard (7.7 %, 61 mmol/mol) treat-
ment groups in the ADVANCE, ACCORD, and the
VADT trial [10]. Although intensive compared with con-
ventional glycaemic control did not result in significant
differences for all-cause and CVD mortality, the risk of
microvascular complications including kidney disease
was lower in more intensively treated patients in these
interventional trials [27, 28]. While our patients already
had CKD at enrollment, it is possible that improved
metabolic control retards the progression of already
existing CKD. This may also reduce CVD morbidity and
mortality in the long-term because any progression of
CKD is associated with an exponential increase in CVD
risk [2, 29].
CKD can be associated with anemia, which may limit
the utility of HbA1c for diagnosing DM and assessing
glycaemic control; HbA1C levels tend to be lower if
renal anemia is present, due to a shortened life span of
erythrocytes [30]. Indeed, we found a slight but significant
positive correlation between hemoglobin and HbA1C.
However, in the majority of patients hemoglobin values
were in the normal range and there was no difference in













Fig. 1 Histogram of observed hemoglobin A1C (HbA1C) values in 1842 patients with diabetes mellitus and stage 3 CKD and/or overt proteinuria,
for conversion of HbA1C into IFCC units (mmol/mol): (10.93 × HbA1C in %)-23.5
Table 4 Correlates of median HbA1C levels >7.0 % (53 mmol/mol) according to stepwise logistic regression analysis (final model)
Indicators a, b Regression coefficient a Standard error a Odds ratio a 95 % confidence interval a P-value a
Body mass index (per 1 kg/m2 increase) 0.0374 0.0091 1.038 1.020–1.057 <0.0001
Hemoglobin (per 1 g/dL increase) c 0.1060 0.0323 1.112 1.044–1.184 0.0010
Antidiabetic treatment strategies b
Oral anti-diabetic drugs alone, any (n = 426) 0.2177 0.1566 1.243 0.915–1.690 0.16
Oral anti-diabetic drugs plus insulin (n = 141) 1.4428 0.2159 4.233 2.772–6.462 <0.0001
Insulin alone (n = 699) 1.7288 0.1427 5.634 4.260–7.452 <0.0001
N = 266 observations were excluded from the analysis due to combinations that were used less frequently and missing values
a According to the final model; age, gender, BMI, duration of CKD, physical activity, eGFR, hemoglobin, CRP, and antidiabetic medication were used as variables in
the initial model
b Dietary treatment was used as the reference category for any group of antidiabetic therapy
c For conversion into SI units (mmol/L): multiply with 0.62
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the mean hemoglobin concentrations between patients
below and above the median HbA1C value. In addition,
hemoglobin but not HbA1C was positively correlated with
eGFR, confirming previous findings [31].
A further important finding of our study is that antidi-
abetic treatment patterns differed from the general dia-
betes population and were overall highly variable. A
total of slightly more than 50 % was treated with insulin-
based therapies. In a German general type 2 diabetes
population the portion of insulin-based therapies was
31 % which is 20 % lower than in the patients currently
studied [32]. More than 40 % of our patients were
treated with insulin alone which is distinctly higher as in
general diabetes cohorts including German cohorts in
which only 10–20 % are treated with insulin monother-
apy [24, 33, 34]. Only one third of our patients was
treated with oral glucose-lowering medication with or
without insulin. In the German general diabetes popula-
tion at least 60 to 70 % of the patients receive any oral
antidiabetic medication [23, 24, 32]. One quarter of our
cohort was treated with oral antidiabetic agents alone
comparing with up to 75 % in general diabetes cohorts
[24, 35]. However, this portion is apparently lower in
German diabetes cohorts; at about 40 to a maximum of
60 % [23, 24]. Different treatments were associated with
different levels of metabolic control. The use of insulin,
alone or in the combination with oral antidiabetic drugs,
was accompanied by a 4 to nearly 6 times higher prob-
ability of having HbA1C values >7.0 % (53 mmol/mol).
Conversely, the use of oral glucose-lowering drugs alone,
namely metformin, glinides, DPP-4 inhibitors, or the
combination of metformin with DPP-4 inhibitors was
not associated with such probability except sulfonyl-
ureas. The observational nature of the study precludes
drawing conclusions on cause and effect when consider-
ing these differences in metabolic control in patients
receiving different therapies and a number of factors
may play a role. Thus it is not unlikely that patients
whose diabetes was difficult to treat were switched to
sulfonylureas or insulin, explaining at least in part higher
HbA1C levels in these patients. On the other hand
higher HbA1C targets may intentionally have been
chosen in some patients. The K/DOQI guideline for
CKD patients recommends that in patients “with co-
morbidities or limited life expectancy and risk of
hypoglycemia”, target HbA1C should be extended above
7.0 % [21]. While implementation of this recommenda-
tion could explain higher HbA1C levels in some patients,
it appears unlikely that this applies to the majority of the
insulin treated patients, given their younger age, no differ-
ence in eGFR, and only a slightly higher rate in prevalent
CVD. On the other hand, their UACR was higher, the dur-
ation of CKD longer, and their physical activity was lower
indicating more advanced diabetic disease. Furthermore,
the K/DOQI guidelines recommend a HbA1C treatment
target of >7.0 % for patients at risk of hypoglycemia, “in-
cluding those treated with insulins or sulfonylureas and/or
have advanced CKD” [21]. The amplified risk for
hypoglycaemia in CKD is well documented, especially for
patients treated with insulin or sulfonylureas [5]. Indeed
the mean HbA1C levels in patients receiving sulfonylureas
in combination with metformin or insulin were higher
than in many other groups, but this did not apply to those
treated with sulfonylureas only. Conversely, the presence
of a lower HbA1C in the orally treated patients (except
those having sulfonylureas) is unlikely due to more fre-
quent episodes of hypoglycaemia as metformin and DPP-
4 inhibitors do not cause hypoglycaemia and the risk for
hypoglycaemia is very low with the use of glinides, espe-
cially in CKD stages lower than stage G4 [21]. Although
patients difficult to treat with oral antidiabetic agents may
have been switched to insulin, it is nevertheless note-
worthy that a substantial proportion of patients was well
controlled on oral agents only, indicating their potential
value in the presence of CKD. Apart from the different an-
tidiabetic therapies any increase in BMI was also signifi-
cantly related to an HbA1C of >7.0 % (53 mmol/mol) and
may point towards a subgroup of patients whose DM is
more difficult to treat due to increased insulin resistance.
Irrespective of the underlying reasons the association
of insulin use with worse metabolic control has previ-
ously also been observed in other patient populations. A
very large retrospective analysis compared patients with
type 2 DM aged 50 years and older, in whom treatment
was escalated from oral monotherapy to either a com-
bination therapy of different oral antidiabetic drugs or to
a regimen that included insulin. The use of insulin treat-
ment was associated with an increase in HbA1C (8.3 %
versus 7.7 % in the oral combination group), increased
mortality (HR 1.49), and the increased likelihood of a
first large-vessel disease event [36]. In another retro-
spective study in type 2 DM patients from Germany, pa-
tients who were prescribed insulin or sulfonylurea, any
combination of insulin with oral antidiabetic drugs, or
the combination of sulfonylurea with metformin were
least likely to achieve an intensive HbA1C target [34].
Another confounding influence is based on the fact
that drug licenses constrain the prescription depending
on the level of kidney function. This is of particular rele-
vance for metformin, which at the time of study enroll-
ment and until recently was not approved in Germany
for patients with an eGFR below 60 mL/min/1.73 m2
(now changed to below 45 ml/min/1.73 m2). Accordingly
the eGFR was higher in those receiving metformin and the
overall rate of metformin use in our cohort was <20 %.
This is distinctly lower as compared with current data from
the U.S. National Health and Nutrition Examination Sur-
vey (NHANES) in which the rates of metformin use were
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48.6 % and 57.4 % in eGFR ranges of 30 to 45 and >45 to
60 mL/min/1.73 m2 [37]. It should be noted that there is
an ongoing debate whether the current thresholds for met-
formin use as suggested by guidelines may be too restrict-
ive [38]. The American Diabetes Association and the
European Association for the Study of Diabetes stated that
the England National Clinical Guideline for Management
in Primary and Secondary Care from the National Institute
for Health and Care Excellence (NICE) [39] is more evi-
dence based, generally allowing metformin use down to an
eGFR of 30 mL/min/1.73 m2, with dose reduction advised
at 45 mL/min/1.73 m2 [38–40]. This European guideline
from 2009 may have prompted the German doctors as
well, to prescribe metformin despite an eGFR of below
60 mL/min/1.73 m2.
Apart from its observational nature, there are further
limitations of our study. We have no information on
treatment duration and medication history, which would
have allowed a better understanding on why patients
were on particular therapies. In this regard there exists
the possibility that patients on insulin are presumably
the ones with more advanced disease with its attendant
higher risk of complications and higher HbA1C. As a
consequence, the treating physicians may have tended to
use insulin in patients with a higher HbA1C and with
complications when compared to patients with lower
HbA1C. Thus, a causal association between the use of
insulin and higher HbA1C and complications cannot be
proven. Nevertheless, the cross-sectional nature of this
baseline analysis prohibits conclusions on associations
with outcomes. Although HbA1C still remains the
cornerstone for the estimation of glycaemic control and
as most clinical trials have used it [41], it is sensitive to
episodes of hypoglycaemia.
The strength of the study includes its size and the as-
sessment of different types of antidiabetic medication.
Medication information was directly obtained from the
patient, possibly overcoming some of the uncertainties
of implementation and validity of prescription orders in
patients treated by more than one physician. HbA1C
values were all determined in a central lab using identi-
cal methodology and interference from carbamylated
hemoglobin could be excluded by using a specific im-
munoassay [42].
Conclusions
Within a large cohort of referred patients with DM and
CKD stage 3 and/or overt proteinuria, the overall treat-
ment quality of DM was satisfactory, but relevant pro-
portions of patients had HbA1C values below or above
the recommended target range. The underlying treat-
ment patterns differed from general diabetes cohorts
with a remarkably high proportion of more than 50 %
receiving insulin-based therapies which were associated
with an increased probability of HbA1C levels >7 %
(53 mmol/mol). Future follow-up will reveal whether the
level of control of DM in the presence of CKD and/or
the choice of antidiabetic agent/s is associated with renal
and CVD outcomes and differences in mortality.
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